Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
- PMID: 26735310
- DOI: 10.3109/10428194.2015.1131278
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting)
Abstract
The European Society for Blood and Marrow Transplantation Chronic Malignancies Working Party held a preceptorship meeting in Turin, Italy on 25-26 September 2014, to discuss the role of stem cell transplantation (SCT) in the treatment of multiple myeloma and other plasma cell disorders. Scientists and clinicians working in the field gathered to discuss a variety of topics including the results of recent clinical trials, basic research, the concept of minimal residual disease, and immune modulation. As individual presentations revealed, important advances have occurred in our understanding of the pathophysiology of myeloma and the role that SCT, along with other forms of immunotherapy, plays in treating it. Each presentation stimulated discussion and exchange of ideas among the attendants. We decided to summarize and, importantly, to update the meeting proceedings in this review to share stimulating discussions and ideas on potentially novel treatment strategies among clinicians.
Keywords: Multiple myeloma; new drugs; stem cell transplantation.
Similar articles
-
Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.J Hematother. 1996 Aug;5(4):339-49. doi: 10.1089/scd.1.1996.5.339. J Hematother. 1996. PMID: 8877709 Clinical Trial.
-
Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.Bone Marrow Transplant. 2001 Oct;28(8):725-35. doi: 10.1038/sj.bmt.1703254. Bone Marrow Transplant. 2001. PMID: 11781623 Review.
-
The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.Eur J Haematol. 2015 Feb;94(2):109-14. doi: 10.1111/ejh.12412. Epub 2014 Jul 28. Eur J Haematol. 2015. PMID: 25039659 Review.
-
The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing.Clin J Oncol Nurs. 2007 Aug;11(4):579-89. doi: 10.1188/07.CJON.579-589. Clin J Oncol Nurs. 2007. PMID: 17723970 Free PMC article. Review.
-
The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.Ann Oncol. 2000;11 Suppl 1:55-8. Ann Oncol. 2000. PMID: 10707780 Review.
Cited by
-
Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.Haematologica. 2018 Mar;103(3):514-521. doi: 10.3324/haematol.2017.181339. Epub 2017 Dec 7. Haematologica. 2018. PMID: 29217776 Free PMC article. Clinical Trial.
-
An overview of multiple myeloma: A monoclonal plasma cell malignancy's diagnosis, management, and treatment modalities.Saudi J Biol Sci. 2024 Feb;31(2):103920. doi: 10.1016/j.sjbs.2023.103920. Epub 2023 Dec 30. Saudi J Biol Sci. 2024. PMID: 38283805 Free PMC article. Review.
-
Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.Am J Cancer Res. 2020 Mar 1;10(3):870-883. eCollection 2020. Am J Cancer Res. 2020. PMID: 32266096 Free PMC article.
-
Increased circulating CD4+FOXP3+ T cells associate with early relapse following autologous hematopoietic stem cell transplantation in multiple myeloma patients.Oncotarget. 2018 Jun 5;9(43):27305-27317. doi: 10.18632/oncotarget.25553. eCollection 2018 Jun 5. Oncotarget. 2018. PMID: 29930767 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials